JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Metastatic Merkel Cell Carcinoma After Simultaneous Pancreas-Kidney Transplantation: Fatal Outcomes

Journal of Drugs in Dermatology : Jdd +

|

May 6, 2024

|

May 6, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Merkel cell carcinoma (MCC) is a rare skin cancer. Organ transplant recipients with MCC face poor outcomes, as standard immunotherapy risks transplant rejection, and current treatments failed in two reviewed cases.

Area Of Science

  • Oncology
  • Transplantation Immunology

Background

  • Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
  • Immunosuppression, common in organ transplant recipients (OTRs), elevates MCC risk and worsens prognosis.
  • Treating MCC in OTRs is complex due to the risk of transplant rejection with standard checkpoint inhibitor immunotherapy.

Observation

  • This review examines two simultaneous pancreas-kidney transplant recipients diagnosed with MCC.
  • Both patients experienced disease progression and mortality despite treatment modifications.
  • Immunosuppression was discontinued in one patient, and immunotherapy was initiated.

Findings

  • The two reviewed cases of MCC in simultaneous pancreas-kidney transplant recipients resulted in fatal metastatic disease.
  • Standard treatment approaches, including immunotherapy and immunosuppression management, proved ineffective.
  • The aggressive nature of MCC in this population highlights significant challenges in management.

Implications

  • There is a critical need for novel, multidisciplinary treatment strategies for MCC in organ transplant recipients.
  • Further research is required to understand the interplay between immunosuppression and MCC pathogenesis in OTRs.
  • Developing safer and more effective therapeutic options is essential to improve survival rates for OTRs with MCC.